EASL has been actively working to beat liver disease, including NAFLD & NASH, through its schools and key event, the NAFLD Summit. EASL has also developed a Policy Statement on the measures required to prevent and treat this common progressive condition. Globally, 1 in 4 people are living with fatty liver disease, with obesity, alcohol consumption, and sedentary lifestyles as key contributors.
Fatty liver is a silent but deadly epidemic with many people remaining asymptomatic well into the advanced stages of disease. The development of new therapies, the use of biomarkers in NAFLD, and how microbiota and genes can modulate alcohol-related liver disease (ALD) are current key research questions that will be addressed during The Digital ILC 2020.
Digital ILC 2020 highlights: NAFLD pharmacological therapy session
What progress is underway in NAFLD pharmacological therapy? How has this active research field evolved since ILC 2019? Watch this video to get the “NAFLD pharmacological therapy” highlights from the session co-chair, Prof. Sven Francque.
Explore the Metabolism, Alcohol and Toxicity Track at the Digital International Liver Congress™ 2020
Abstract sessions
Abstract session: NAFLD – Non invasive assessment27 August 2020 11:00 – 12:30 Chairs: Victor de Lédinghen (France), Manuel Romero Gomez (Spain) |
Abstract session: Alcohol associated liver disesase27 August 2020 11:00 – 12:30 Chairs: Marsha Morgan (United Kingdom), Alexandre Louvet (France) |
Abstract session: NAFLD – Clinical except therapy27 August 2020 15:30 – 17:00 Chairs: Luca Miele (Italy), Raluca Pais (France) |
Abstract session: NAFLD – Pharmacological therapy28 August 2020 11:00 – 12:30 Chairs: Elisabetta Bugianesi (Italy), Sven Francque (Belgium) |
Abstract session: NAFLD – Target identification and drug pipeline28 August 2020 15:30 – 17:00 Chairs: Frank Tacke (Germany), Luca Valenti (Italy) |
Abstract session: NAFLD – Experimental29 August 2020 11:00 – 12:30 Chair: Amalia Gastaldelli (Italy) |
Meet the experts
Meet the Experts: Non-invasive assessment in NAFLD27 August 2020 09:15 – 09:45 Chairs: Massimo Pinzani (United Kingdom), Maja Thiele (Denmark) |
Interactive sessions
Optimal endpoints in NAFLD clinical trials – Histology or non-invasive biomarkers and imaging?27 August 2020 17:00 – 18:00 Chairs: Manal Abdelmalek (United States), Mattias Ekstedt (Sweden) |
Precision medicine for the management of NAFLD – Are we there yet?29 August 2020 15:30 – 17:00 Stefano Romeo (Sweden) |
Poster tours
Poster tour: NAFLD: Clinical aspects except therapy27 August 2020 12:30 – 13:00 Chair: Salvador Augustin, Spain |
Poster tour: NAFLD: Diagnostics and non-invasive assessment27 August 2020 15:00 – 15:30 Chair: Isabel Graupera (Spain) |
Poster tour: NAFLD: Experimental and pathophysiology28 August 2020 12:30 – 13:00 Chair: Tom Lüdde, Germany |
Poster tour: NAFLD: Therapy28 August 2020 15:00 – 15:30 Chair: Francesca Ponziani, Italy |
Poster tour: Alcoholic liver disease29 August 2020 12:30 – 13:00 Chair: Philippe Mathurin (France) |
Poster tour: Acute liver failure and drug induced liver injury29 August 2020 15:00 – 15:30 Chair: Maria Isabel Lucena (Spain) |
Wrap up session
Digital ILC 2020 wrap up session – NAFLD/NASH/Alcoholic liver disease
29 August 2020 18:08 – 18:28
Chair: William Alazawi (United Kingdom)
Prepare yourself for the Digital ILC 2020
Selected articles from the Journal of Hepatology:
- NAFLD in pregnancy is associated with adverse maternal and perinatal outcomes
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- NAFLD as a driver of chronic kidney disease
|
Discover over 320 dedicated resources on EASL CAMPUS. |
Obesity is feeding the rise in NAFLD across Europe |
|
(Re)discover the Best of ILC 2019 Slide Deck |
A snapshot of NAFLD, a looming public health crisis worldwide |
|
View over 160 open-access resources from the NAFLD Summit 2019 |
Review the open-access content from the NAFLD Summit 2019 |
